Emerging Resistance to Novel β-Lactam β-Lactamase Inhibitor Combinations in <i>Klebsiella pneumoniae</i> bearing KPC Variants.

ABSTRACT:

Background

Klebsiella pneumoniae carbapenemase (KPC) variants, predominantly KPC-2 and KPC-3, are significant global resistance mechanisms. KPC-2 and KPC-3 confer resistance to a broad range of β-lactams, including carbapenems, while remaining susceptible to ceftazidime-avibactam (CZA). Recently, new KPC variants have developed resistance to CZA through mutations, insertions, or deletions in regions such as the Ω-loop, 240-loop (237-243 aa), and 270-loop (266-275 aa). This study aimed to investigate the collateral resistance to cefiderocol (FDC) and cefepime/zidebactam (FPZ) among isolates with these mutations.

Methods

Fifteen clinical isolates of KPC-producing Klebsiella spp. were analyzed, representing 15 distinct variants. Antimicrobial susceptibility testin

SUBMITTER: Hamza M 

PROVIDER: S-EPMC12047877 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature